STOCK TITAN
  1. Home
  2. News
  3. APDN

Applied Dna Sciences Inc - APDN STOCK NEWS

Welcome to our dedicated news page for Applied Dna Sciences (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Applied Dna Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Applied Dna Sciences's position in the market.

News
Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) partners with Alphazyme to scale-up manufacturing of Linea RNA polymerase (RNAP) to meet growing demand for Linea IVT platform. The collaboration aims to increase RNAP manufacturing capacity, reduce unit costs of goods, and coincide with the Company's planned initiation of GMP manufacturing for Linea DNA IVT templates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.57%
Tags
none
-
News
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) will present Linea IVT and Linea DNA platforms at the 24th Annual World Vaccine Congress. Sales team members will be available for meetings during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.08%
Tags
none
-
News
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) announced first-quarter fiscal 2024 financial results. The company is on track to initiate first-phase GMP production capacity for mRNA critical starting materials during the first half of calendar 2024. The initial facility capacity is projected to enable up to $15 million of Linea IVT revenue annually. The company also announced the completion of an equity offering to support the initial phase of the GMP plan and timeline for critical starting materials in the production of mRNA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
earnings
News
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) will release its first quarter fiscal 2024 financial results on February 8, 2024, after market close. A conference call for analysts and investors will be held the same day at 4:30 p.m. ET to discuss the financial results and recent accomplishments. The call will be accessible via dial-in and live webcast, with a replay available for 7 days. An accompanying slide presentation will be available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences earnings
-
News
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) has closed a direct offering of common stock and issued unregistered warrants to certain institutional investors. The company also amended the exercise price and expiration dates of previously issued common stock warrants. The net proceeds from the offering will be used for therapeutic DNA production services and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) has entered into securities purchase agreements with existing institutional investors for the issuance and sale of 5,644,061 shares of common stock at a purchase price of $0.609 per share in a registered direct offering. In a concurrent private placement, the company has also agreed to issue and sell unregistered warrants to purchase up to 11,288,122 shares of its common stock. The warrants have an exercise price of $0.609 per share and will become exercisable on the first trading day after receipt of shareholder approval. Additionally, the company will reduce the exercise price of 3,055,139 common stock warrants previously issued to the investors and extend warrant expiration dates into 2028, subject to approval by the company's stockholders at a stockholder meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
offering
News
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) and Kudo Biotechnology (Kudo Bio) have entered into a joint development agreement to integrate Applied DNA's Linea IVT platform into Kudo Bio's commercial mRNA manufacturing workflows. The agreement aims to optimize mRNA quality, yields, and mitigate contamination by double-stranded RNA (dsRNA) at manufacturing scale. Upon successful completion, the joint workflow is planned for commercial launch in the second half of calendar 2024. The Linea IVT Platform is expected to provide advantages over conventional mRNA manufacturing methods, including the prevention or reduction of dsRNA contamination and reduced mRNA manufacturing turn-around-times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
none
-
News
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) announced consolidated financial results for its fourth quarter ended September 30, 2023. The company's total revenues were approximately $780 thousand, a decrease from $3.6 million for the same period in the prior fiscal year. Operating loss decreased to $4.2 million for the three-month period ended September 30, 2023, as compared to $4.3 million for the fourth quarter of fiscal 2022. Net loss was $3.6 million for the three-month period ended September 30, 2023, compared to $665 thousand for the fourth quarter of 2022. Cash and cash equivalents stood at $7.2 million on September 30, 2023, compared with $10.8 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.52%
Tags
earnings
-
News
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
Rhea-AI Summary
Applied DNA Sciences, Inc. (NASDAQ:APDN) will release its Q4 and full year 2023 financial results on December 7, 2023, after the market close. The company will host a conference call to discuss the results and answer questions at 4:30 p.m. ET. Details for accessing the call and webcast are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
conferences earnings
News
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
Rhea-AI Summary
Applied DNA Sciences, Inc. (APDN) announced a follow-on order for Linea DNA valued above the mid-six figures for a global manufacturer of in vitro diagnostics. Deliveries are expected to commence from March 31, 2024, through December 31, 2024. Dr. James A. Hayward, president and CEO, highlighted the strong demand for IVD-related applications for Linea DNA, emphasizing the potential for high-margin recurring revenues and incremental revenues through new customer acquisition and expanded use by existing customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
Stock APDN logo
Applied Dna Sciences Inc

Nasdaq:APDN

APDN Rankings

N/A Ranked by Market Cap
#4756 Ranked by Stock Gains
N/A Ranked by Dividends

APDN Stock Data

5.85M
13.60M
12.32%
19.23%
1.6%
Cyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing
Manufacturing
Link
US
Stony Brook

About APDN

we keep life real and safe by providing botanical-dna based security and authentication solutions and services that protect assets, products, brands, supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.